A dual role of 12/15-lipoxygenase in LPS-induced acute renal inflammation and injury

Ahmed A. Elmarakby, Ahmed S. Ibrahim, Mohamed A. Katary, Nehal M. Elsherbiny, Mohamed El-Shafey, Ahmed M. Abd-Elrazik, Rafik A. Abdelsayed, Krishna Rao Maddipati, Mohamed Al-Shabrawey

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recent studies suggest a potential role of bioactive lipids in acute kidney injury induced by lipopolysaccharide (LPS). The current study was designed to determine the profiling activities of various polyunsaturated fatty acid (PUFA) metabolizing enzymes, including lipoxygenases (LO), cyclooxygenase, and cytochrome P450 in the plasma of LPS-injected mice using LC-MS. Heat map analysis revealed that out of 126 bioactive lipids screened, only the 12/15-LO metabolite, 12-HETE, had a significant (2.24 ± 0.4) fold increase relative to control (P = 0.0001) after Bonferroni Correction (BCF α = 0.003). We then determined the role of the 12/15-LO in LPS-induced acute kidney injury using genetic and pharmacological approaches. Treatment of LPS injected mice with the 12/15-LO inhibitor, baicalein, significantly reduced levels of renal injury and inflammation markers including urinary thiobarbituric acid reactive substance (TBARs), urinary monocyte chemoattractant protein-1 (MCP-1), renal interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Similarly, knocking-out of 12/15-LO reduced levels of renal inflammation and injury markers elicited by LPS injection. Next, we tested whether exogenous supplementation with docosahexaenoic acid (DHA) as a substrate would divert the role of 12/15-LO from being pro-inflammatory to anti-inflammatory via increased production of the anti-inflammatory metabolite. DHA treatment restored the decreased in plasma level of resolvin D2 (RvD2) and reduced renal injury in LPS-injected mice whereas DHA treatment failed to provide any synergistic effects in reducing renal injury in LPS injected 12/15-LO knock-out mice. The ability of RvD2 to protect kidney against LPS-induced renal injury was further confirmed by exogenous RvD2 which significantly reduced the elevation in renal injury in LPS injected mice. These data suggest a double-edged sword role of 12/15-LO in LPS-induced acute renal inflammation and injury, depending on the type of substrate available for its activity.

Original languageEnglish (US)
Pages (from-to)1669-1680
Number of pages12
JournalBiochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Volume1864
Issue number11
DOIs
StatePublished - Nov 2019

Fingerprint

Acute Kidney Injury
Lipopolysaccharides
Inflammation
Kidney
Docosahexaenoic Acids
Wounds and Injuries
Lipoxygenase Inhibitors
Anti-Inflammatory Agents
12-Hydroxy-5,8,10,14-eicosatetraenoic Acid
Lipoxygenases
12-15-lipoxygenase
Lipids
Thiobarbituric Acid Reactive Substances
Chemokine CCL2
Prostaglandin-Endoperoxide Synthases
Unsaturated Fatty Acids
Knockout Mice
Cytochrome P-450 Enzyme System
Interleukin-6
Therapeutics

Keywords

  • 12/15-lipoxygenase
  • Baicalein
  • DHA
  • Inflammation
  • LPS
  • Renal injury
  • Resolvin

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

A dual role of 12/15-lipoxygenase in LPS-induced acute renal inflammation and injury. / Elmarakby, Ahmed A.; Ibrahim, Ahmed S.; Katary, Mohamed A.; Elsherbiny, Nehal M.; El-Shafey, Mohamed; Abd-Elrazik, Ahmed M.; Abdelsayed, Rafik A.; Maddipati, Krishna Rao; Al-Shabrawey, Mohamed.

In: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, Vol. 1864, No. 11, 11.2019, p. 1669-1680.

Research output: Contribution to journalArticle

Elmarakby, Ahmed A. ; Ibrahim, Ahmed S. ; Katary, Mohamed A. ; Elsherbiny, Nehal M. ; El-Shafey, Mohamed ; Abd-Elrazik, Ahmed M. ; Abdelsayed, Rafik A. ; Maddipati, Krishna Rao ; Al-Shabrawey, Mohamed. / A dual role of 12/15-lipoxygenase in LPS-induced acute renal inflammation and injury. In: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids. 2019 ; Vol. 1864, No. 11. pp. 1669-1680.
@article{59ce45fbbd8647c98b612a9faeabcc2a,
title = "A dual role of 12/15-lipoxygenase in LPS-induced acute renal inflammation and injury",
abstract = "Recent studies suggest a potential role of bioactive lipids in acute kidney injury induced by lipopolysaccharide (LPS). The current study was designed to determine the profiling activities of various polyunsaturated fatty acid (PUFA) metabolizing enzymes, including lipoxygenases (LO), cyclooxygenase, and cytochrome P450 in the plasma of LPS-injected mice using LC-MS. Heat map analysis revealed that out of 126 bioactive lipids screened, only the 12/15-LO metabolite, 12-HETE, had a significant (2.24 ± 0.4) fold increase relative to control (P = 0.0001) after Bonferroni Correction (BCF α = 0.003). We then determined the role of the 12/15-LO in LPS-induced acute kidney injury using genetic and pharmacological approaches. Treatment of LPS injected mice with the 12/15-LO inhibitor, baicalein, significantly reduced levels of renal injury and inflammation markers including urinary thiobarbituric acid reactive substance (TBARs), urinary monocyte chemoattractant protein-1 (MCP-1), renal interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Similarly, knocking-out of 12/15-LO reduced levels of renal inflammation and injury markers elicited by LPS injection. Next, we tested whether exogenous supplementation with docosahexaenoic acid (DHA) as a substrate would divert the role of 12/15-LO from being pro-inflammatory to anti-inflammatory via increased production of the anti-inflammatory metabolite. DHA treatment restored the decreased in plasma level of resolvin D2 (RvD2) and reduced renal injury in LPS-injected mice whereas DHA treatment failed to provide any synergistic effects in reducing renal injury in LPS injected 12/15-LO knock-out mice. The ability of RvD2 to protect kidney against LPS-induced renal injury was further confirmed by exogenous RvD2 which significantly reduced the elevation in renal injury in LPS injected mice. These data suggest a double-edged sword role of 12/15-LO in LPS-induced acute renal inflammation and injury, depending on the type of substrate available for its activity.",
keywords = "12/15-lipoxygenase, Baicalein, DHA, Inflammation, LPS, Renal injury, Resolvin",
author = "Elmarakby, {Ahmed A.} and Ibrahim, {Ahmed S.} and Katary, {Mohamed A.} and Elsherbiny, {Nehal M.} and Mohamed El-Shafey and Abd-Elrazik, {Ahmed M.} and Abdelsayed, {Rafik A.} and Maddipati, {Krishna Rao} and Mohamed Al-Shabrawey",
year = "2019",
month = "11",
doi = "10.1016/j.bbalip.2019.07.009",
language = "English (US)",
volume = "1864",
pages = "1669--1680",
journal = "Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids",
issn = "1388-1981",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - A dual role of 12/15-lipoxygenase in LPS-induced acute renal inflammation and injury

AU - Elmarakby, Ahmed A.

AU - Ibrahim, Ahmed S.

AU - Katary, Mohamed A.

AU - Elsherbiny, Nehal M.

AU - El-Shafey, Mohamed

AU - Abd-Elrazik, Ahmed M.

AU - Abdelsayed, Rafik A.

AU - Maddipati, Krishna Rao

AU - Al-Shabrawey, Mohamed

PY - 2019/11

Y1 - 2019/11

N2 - Recent studies suggest a potential role of bioactive lipids in acute kidney injury induced by lipopolysaccharide (LPS). The current study was designed to determine the profiling activities of various polyunsaturated fatty acid (PUFA) metabolizing enzymes, including lipoxygenases (LO), cyclooxygenase, and cytochrome P450 in the plasma of LPS-injected mice using LC-MS. Heat map analysis revealed that out of 126 bioactive lipids screened, only the 12/15-LO metabolite, 12-HETE, had a significant (2.24 ± 0.4) fold increase relative to control (P = 0.0001) after Bonferroni Correction (BCF α = 0.003). We then determined the role of the 12/15-LO in LPS-induced acute kidney injury using genetic and pharmacological approaches. Treatment of LPS injected mice with the 12/15-LO inhibitor, baicalein, significantly reduced levels of renal injury and inflammation markers including urinary thiobarbituric acid reactive substance (TBARs), urinary monocyte chemoattractant protein-1 (MCP-1), renal interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Similarly, knocking-out of 12/15-LO reduced levels of renal inflammation and injury markers elicited by LPS injection. Next, we tested whether exogenous supplementation with docosahexaenoic acid (DHA) as a substrate would divert the role of 12/15-LO from being pro-inflammatory to anti-inflammatory via increased production of the anti-inflammatory metabolite. DHA treatment restored the decreased in plasma level of resolvin D2 (RvD2) and reduced renal injury in LPS-injected mice whereas DHA treatment failed to provide any synergistic effects in reducing renal injury in LPS injected 12/15-LO knock-out mice. The ability of RvD2 to protect kidney against LPS-induced renal injury was further confirmed by exogenous RvD2 which significantly reduced the elevation in renal injury in LPS injected mice. These data suggest a double-edged sword role of 12/15-LO in LPS-induced acute renal inflammation and injury, depending on the type of substrate available for its activity.

AB - Recent studies suggest a potential role of bioactive lipids in acute kidney injury induced by lipopolysaccharide (LPS). The current study was designed to determine the profiling activities of various polyunsaturated fatty acid (PUFA) metabolizing enzymes, including lipoxygenases (LO), cyclooxygenase, and cytochrome P450 in the plasma of LPS-injected mice using LC-MS. Heat map analysis revealed that out of 126 bioactive lipids screened, only the 12/15-LO metabolite, 12-HETE, had a significant (2.24 ± 0.4) fold increase relative to control (P = 0.0001) after Bonferroni Correction (BCF α = 0.003). We then determined the role of the 12/15-LO in LPS-induced acute kidney injury using genetic and pharmacological approaches. Treatment of LPS injected mice with the 12/15-LO inhibitor, baicalein, significantly reduced levels of renal injury and inflammation markers including urinary thiobarbituric acid reactive substance (TBARs), urinary monocyte chemoattractant protein-1 (MCP-1), renal interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Similarly, knocking-out of 12/15-LO reduced levels of renal inflammation and injury markers elicited by LPS injection. Next, we tested whether exogenous supplementation with docosahexaenoic acid (DHA) as a substrate would divert the role of 12/15-LO from being pro-inflammatory to anti-inflammatory via increased production of the anti-inflammatory metabolite. DHA treatment restored the decreased in plasma level of resolvin D2 (RvD2) and reduced renal injury in LPS-injected mice whereas DHA treatment failed to provide any synergistic effects in reducing renal injury in LPS injected 12/15-LO knock-out mice. The ability of RvD2 to protect kidney against LPS-induced renal injury was further confirmed by exogenous RvD2 which significantly reduced the elevation in renal injury in LPS injected mice. These data suggest a double-edged sword role of 12/15-LO in LPS-induced acute renal inflammation and injury, depending on the type of substrate available for its activity.

KW - 12/15-lipoxygenase

KW - Baicalein

KW - DHA

KW - Inflammation

KW - LPS

KW - Renal injury

KW - Resolvin

UR - http://www.scopus.com/inward/record.url?scp=85070214814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070214814&partnerID=8YFLogxK

U2 - 10.1016/j.bbalip.2019.07.009

DO - 10.1016/j.bbalip.2019.07.009

M3 - Article

C2 - 31349026

AN - SCOPUS:85070214814

VL - 1864

SP - 1669

EP - 1680

JO - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

JF - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

SN - 1388-1981

IS - 11

ER -